News | December 16, 2010

Customized Solutions Meet the Demands of an Evolving Radiology Market

December 16, 2010 – Bracco Imaging demonstrated how its customized evidence-based diagnostic imaging solutions are meeting the demands of an evolving radiology market at the Radiological Society of North America (RSNA) meeting. The company is also showing regulatory progress related to its contrast media in computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine, cardiac catheterization, interventional/diagnostic radiology and its contrast delivery systems.

“A number of factors are shaping the evolution of radiology today, including rapid innovation, cost control and an acute awareness of product safety,” said Carlo Medici, head of global commercial operations of Bracco Imaging and president and CEO, Bracco Diagnostics.

The company’s Isovue (iopamidol injection) is available in a convenient range of iodine concentrations and packaging options, making it the top osmolar contrast media agent in the United States.

The company also continues to see robust growth stemming from its 2008 acquisition of E-Z-EM, one of the most recognized brands among radiologists and gastrointestinal (GI) physicians. Among these are the company’s injector and data management systems, which enable radiologists, administrators and technologists to gain workflow efficiencies, imaging optimization and patient safety benefits. Also, through this acquisition, Bracco is now the only provider of barium-based oral imaging products.

Safety, Efficacy and Efficiency in MRI

The company’s gadolinium-based contrast agents (GBCAs) - MultiHance (gadobenate dimeglumine) and ProHance (gadoteridol) - are increasingly the MRI agents of choice by radiologists in more than 2,000 healthcare facilities in the United States.

MultiHance was the first and only contrast agent approved for MRI of the central nervous system (CNS) in the United States, with twice the relaxivity compared to other tested extracellular contrast agents. This means greater contrast-to-noise and lesion-to-brain ratio, which may lead to improved visualization. ProHance is the only macrocyclic gadolinium contrast agent available in the United States, with an exceptionally stable Gd chelate.

Nephrogenic systemic fibrosis (NSF), a rare and potentially life threatening syndrome in patients with renal impairment, has been associated with GBCAs. This has fueled significant clinical and scientific activity in attempts to determine the etiology of this disease. In response the U.S. Food and Drug Administration (FDA) recently published new guidelines defining specific classes of GBCAs based on risk of causing NSF. In a briefing document dated December 8, 2009, the FDA wrote: “Of the 5 GBCs considered, the higher risk is associated with Omniscan, Magnevist, and OptiMARK while the lowest risk is associated with ProHance and MultiHance.”

Further, the American College of Radiology that radiologists should administer GBCAs to renally impaired patients only where necessary. The ACR also advised using the lowest possible dose.

Studies demonstrate that MultiHance provides significantly greater diagnostic information and lesion visualization when compared to two other commonly used contrast agents used at an equivalent dose. It is also FDA-approved for intravenous use in MRI of the CNS in children over two years of age.

For more information: usa.braccoimaging.com

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Overlay Init